Stock Events

Stock Events

OmniAb

$1.43

13

+$0.03+2.14% Wednesday 20:00

Statistics

Day High

1.46

Day Low

1.37

52W High

2.2

52W Low

1.25

Volume

577,258

Avg. Volume

-

Mkt Cap

205.86M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

7MayExpected

Q3 2024

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Next

-0.17

-0.14

-0.12

-0.09

Expected EPS

-0.104286

Actual EPS

N/A

Financials

-235.05%Profit Margin

Unprofitable

2021

2022

2023

2024

52.78MRevenue

-124.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OABI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.

Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.

Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.

Gilead Sciences

Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.

Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.

Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.

AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.

Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.

Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Show more...

CEO

Mr. Matthew W. Foehr

Employees

114

Country

United States

ISIN

US68218J1034

Listings

0 Comments

Share your thoughts

FAQ

What is OmniAb stock price today?▼

The current price of OABI is $1.43 USD — it has increased by +2.14% in the past 24 hours. Watch OmniAb stock price performance more closely on the chart.

What is OmniAb stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange OmniAb stocks are traded under the ticker OABI.

Is OmniAb stock price growing?▼

OABI stock has risen by +2.88% compared to the previous week, the month change is a -5.3% fall, over the last year OmniAb has showed a -6.54% decrease.

What is OmniAb market cap?▼

Today OmniAb has the market capitalization of 205.86M

What is OmniAb revenue for the last year?▼

OmniAb revenue for the last year amounts to 52.78M USD.

What is OmniAb net income for the last year?▼

OABI net income for the last year is -124.07M USD.

How many employees does OmniAb have?▼

As of May 07, 2026, the company has 114 employees.

In which sector is OmniAb located?▼

OmniAb operates in the Health & Wellness sector.

When did OmniAb complete a stock split?▼

OmniAb has not had any recent stock splits.

Where is OmniAb headquartered?▼

OmniAb is headquartered in EmeryVille, United States.